CTL109
Preparing for ASH 2025: Pharma’s role in hematology innovation
As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...
J&J presents positive phase 3 results for Darzalex Faspro in smouldering multiple myeloma
The early precursor of active disease accounts for 15% of all newly-diagnosed multiple myeloma cases
Roche announces five-year results for Polivy combination in diffuse large B-cell lymphoma
Approximately 160,000 cases of the aggressive blood cancer are diagnosed globally every year
Sanofi’s rilzabrutinib shows promise in phase 3 immune thrombocytopenia study
Approximately 9.5 per 100,000 people in the US are affected by the rare autoimmune disorder
Regeneron shares positive late-stage results for poze-cemdi in rare blood disorder PNH
Paroxysmal nocturnal haemoglobinuria affects up to 1.5 people per million in the US
Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
The company will present 90 abstracts from across a wide range of haematologic diseases, including results from three pivotal studies in lymphoma and haemophilia
NICE recommends Novartis’ Rydapt for advanced SM treatment
The twice-daily, oral drug improves overall survival of people with the rare blood disorder
Roche, AbbVie hit by clinical hold for Venclexta in myeloma
Safety concerns could hit blockbuster expectations
AbbVie, Roche get FDA OK for broader use of Venclexta
The drug is tipped to become a $2.5bn product by 2024
Roche’s MabThera ends drug drought for serious skin disease
As biosimilars seize market share, Roche finds ways to extend blockbuster's revenues
Ocrevus helps Roche stave off biosimilar threat
Its low price strategy for the CD20-targeting antibody is paying off